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Abstract 
Depending on the cell type studied, the involvement of type II transglutaminase (TGase) has been proposed in almost any event of the 
cell life such as differentiation, apoptosis, growth, aging, cell morphology and adhesion, metastatic apacity or extracellular matrix 
stabilization. In order to define the field(s) where this enzyme may be implicated in chondrocytes, type II TGase expression was studied 
in chondrocytes atdifferent passages which differentiated state was modulated by retinoic acid, dihydrocytochalasin B or staurosporin. 
Results showed that (i) type II TGase expression is not incompatible with type II collagen expression, a main marker of chondrocyte 
differentiation (ii) type II TGase expression is higher when cells are in the exponential phase of growth than when growth arrested (iii) a 
high type II TGase expression does not imply that cells are apoptotic although cell apoptosis correlates with increased type II TGase 
expression (iv) non-adherent cells do not express type II TGase whereas adherent cells do whatever their differentiation state as assessed 
by type II collagen synthesis. These results suggest that, in articular chondrocytes, type II TGase is specifically implicated in the cell 
adhesion capacity. 
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1. Introduction 
Transglutaminases (TGases, R-glutamylpeptide: amine- 
y-glutamyl transferase, EC 2.3.2.13) are a family of Ca 2÷- 
dependant enzymes that catalyse the formation of e-(7- 
glutamyl)lysine-protein cross links and the incorporation 
of primary amines into protein bound glutamine residues 
[1]. Transglutaminases have been characterized based on 
differences in their cellular distribution, immunoreactivity, 
Abbreviations: TGase, transglutaminase; RA, all trans-retinoic a id; 
DHCB, dihydrocytochalasin B; DMSO, dimethylsulfoxide; SDS-PAGE, 
sodium dodecyl sulfate-polyacrylamide gel lectrophoresis; PBS, phos- 
phate buffered saline; Tris-HC1, tris(hydroxymethyl)amino ethane-hy- 
drochloric acid; DTT, dithiothreitol; PMSF, phenylmethanesulphonyl flu- 
oride; PVDF, poly(vinylidene)difluofide; TBS-T, Tris-buffered saline- 
Tween-20; EDTA, ethylenediaminetetraacetic id 
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amino acid sequence, enzymatic properties and most of 
their genes have now been cloned and sequenced (for 
reviews, see [2-4]). Among these, type II transglutami- 
nase, the most studied TGase, is expressed in many tissues 
[5] and its role remains unclear. Type II TGase is a 
cytosolic enzyme but there are increasing lines of evidence 
that it is also localized in the extracellular compartment 
[4,6]. Depending on the cell type studied, it has been 
suggested to be involved in cell growth [7,8], differentia- 
tion [9-11], apoptosis [12-14], capacity to metastise [14- 
16], cell morphology and adhesion [17,18], aging [19] and 
also in extracellular matrix stabilization [6,20-22]. More 
recently, type II TGase has been shown to be able to 
modulate or modify the biological activity of proteins such 
as phospholipases A2 [23] or interleukin-2 [24]. Moreover, 
a GTPase activity of type II TGase has been described 
[25]. 
In a previous paper [26], we showed, on the basis of 
activity measurements, hat rabbit articular chondrocytes in
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culture express two different TGases activities which rela- 
tive proportion differs as a function of passage number: 
one is preferentially expressed at early passages, down 
regulated by retinoic acid, activated by trypsin and prefer- 
entially membrane associated. The other one is up-regu- 
lated upon retinoic acid treatment of cells, inactivated upon 
trypsin treatment of cell lysates and preferentially localized 
in the cytosol. In the present paper, we show that this latter 
TGase activity is due to type II TGase. In order to point 
out the field(s) where this enzyme may play a role in this 
cell type, type II TGase expression was studied in chon- 
drocytes cultured in various conditions aimed to modify a 
cellular event where, in other cell types, the enzyme has 
been shown to be involved. However, there are not any 
culture conditions which are able to modify a single 
parameter ata time: differentiation, age, growth, cell adhe- 
sion or apoptosis. All these parameters were therefore 
assessed, together with type II TGase expression, on a few 
different chondrocyte models which were chosen so that it 
was possible to know whether type II TGase was impli- 
cated or not in one of the parameters studied. In culture, as 
a function of passage number, chondrocytes gradually 
loose their growth capacity [27], a characteristic feature of 
aged cells, as well as they stop type II collagen synthesis 
[28] and acquire a fibroblastic morphology [28,29], both 
signing chondrocyte dedifferentiation. The effect of retinoic 
acid on these cells was also investigated since it rapidly 
induces chondrocyte dedifferentiation [30]. In order to 
discriminate between a relationship concerning type II 
TGase and type II collagen synthesis, or type II TGase and 
cell adhesion, DHCB and staurosporin treatments were 
performed since they both reinduce type II collagen ex- 
pression in dedifferentiated cells [31,32 respectively] while 
preliminary experiments showed that these drugs have a 
quite different effect on chondrocyte adhesion. Type II 
TGase expression as a function of time after cell seeding 
was also examined to assess the cell growth parameter. 
Finally, since these drugs used have been shown to induce 
apoptosis in other cell types ([33,34] for retinoic acid and 
staurosporin, respectively), and since type II TGase has 
been shown to be induced upon apoptosis [12,13,33], we 
also studied whether apoptosis occurred in such treated 
cells. 
2. Materials and methods 
2.1. Materials 
Ham's F12, Dulbecco's modified Eagle medium and 
PBS were purchased from Gibco-BRL and fetal calf serum 
from IBF. Staurosporin was from Boehringer. All reagents 
and apparatus for protein and DNA electrophoresis or for 
Western blotting were from Biorad except agarose which 
was from Appligene. L-[5-3H]Proline (20-50 Ci/mmol), 
Amplify and ECL western blotting reagents were from 
Amersham. The mouse monoclonal antibody CUB-7402 
against ransglutaminase type II [35] was a generous gift 
from Dr. P. J. Birckbichler (Samuel Robert Noble Founda- 
tion, Ardmore, OK). All other eagents were obtained from 
Sigma. 
2.2. Cell culture 
Rabbit articular chondrocytes were released from carti- 
lage slices of 1- to 2-mth-old Fauve de Bourgogne rabbits 
by sequential enzymatic digestion as described by Green 
[36], plated at 25 000 cells/cm 2 in Ham's F12 medium 
containing 10% fetal calf serum and 4 /zg /ml  gentamicin, 
and incubated in a humidified atmosphere of 5% CO 2 and 
95% air at 37°C. Medium was changed 2 days after 
seeding and cells reached confluence in 6 days. These 
confluent primary cultures (P0) were trypsinized, replated 
as described above and subcultured up to passage 4 (P4). 
The medium was changed once during the incubation 
week needed to reach confluency. 
Confluent cultures were treated with medium supple- 
mented with either 3.3 /.tM all-trans-retinoic acid for 48 h 
[30], 3 /xM dihydrocytochalasin B for 14 days [31] or 5 
nM staurosporin for 5 days [32]. Media were changed 
every other day. Control cultures were treated similarly 
with medium alone. Subsequent to DHCB or staurosporin 
treatment, dishes were treated for two days more with 
either medium containing 3.3 /zM retinoic acid or with 
medium alone. 3.3 /.~M RA in medium was prepared from 
a 3.3 mM stock solution prepared in 95% ethanol, stored at 
-20°C. 3 /zM DHCB was prepared from a 3 mM stock 
solution in DMSO, stored at 4°C. A 1 mM staurosporin 
stock solution in DMSO, stored at 4°C, was freshly diluted 
at 1/xM in PBS containing lmg/ml bovine serum albumin 
before being further diluted at 5 nM in culture medium. 
2.3. Collagen synthesis 
Confluent cultures in 25-cm 2 flasks were labelled for 
24 hours with L-[5-3H]proline (50 /zCi/ml) in Dulbecco's 
modified Eagle medium containing 10% fetal calf serum 
supplemented with/3-aminopropionitrile (62.5/zg/ml) and 
sodium ascorbate (25 /zg/ml). After pepsin treatment of 
the whole cultures, collagens were purified by ammonium 
sulfate precipitation [26], cleaved with cyanogen bromide 
[37] and fractionated by 16% SDS-PAGE [28]. Gels were 
processed for fluorography using Amplify according to the 
manufacturer's instructions and exposed to Kodak XAR 
film at - 80°C. 
2.4. Western blot 
Cells in 100 mm culture dishes were rinsed twice with 
5ml of ice-cold PBS (10 mM phosphate buffer (pH 7.5), 
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2.7 mM KCI, 137 mM NaC1) and harvested by scraping 
the cell layers with a rubber policeman in 0.5 ml lysis 
buffer containing 5 mM Tris-HC1 (pH 7.5), 0.25 M su- 
crose, 0.2 mM MgSO4, 2 mM DTT, 0.4 mM PMSF, 5 
/xg/ml leupeptin and 0.4% triton X-100. Cell suspensions 
were stored at -80°C until use. Cells were lysed by 
sonication (2 X 10 s at an amplitude of 7 /xm) and the 
protein concentration was measured using the Bio-Rad 
protein assay and bovine serum albumin as standard. Pro- 
teins were fractionated by 7.5% SDS-PAGE under nonre- 
ducing conditions according to Laemmli [38]. Proteins 
were electrophoretically transferred onto 0.22-/zm pore 
PVDF membrane using a semidry transfer system (Bio- 
Rad). The transfer buffer consisted of 25 mM Tris, 192 
mM glycine, 20% methanol (pH 8.3) [39], and transfer was 
conducted for 30 min at 15 V. The PVDF membrane was 
soaked overnight at room temperature in TBS-T (20 mM 
Tris-HC1 (pH 7.6), 137 mM NaC1, 0.1% Tween-20) con- 
taining 5% nonfat dry milk in order to block nonspecific 
binding. The membrane was washed in TBS-T then incu- 
bated in TBS-T containing the mouse monoclonal antibody 
CUB-7402 against transglutaminase type II (1:250 dilu- 
tion) for 1 h. After extensive washing in TBS-T, the 
membrane was incubated for an hour in TBS-T containing 
an horseradish peroxidase-conjuguated sheep anti-mouse 
antibody (1:5000 dilution). After extensive washing in 
TBS-T, the blot was developed using the ECL Western 
blotting detection reagents (Amersham), following the di- 
rections of the manufacturer. 
2.5. DNA extraction and agarose electrophoresis 
A selective procedure for extraction of the degraded, 
low-molecular-weight DNA from apoptotic ells was per- 
formed as described in [40] with modifications. Cells were 
removed from their substratum by treatment with trypsin- 
EDTA, sedimented and the pellet was suspended in 1 ml 
of Hank's buffered salt solution. Cells were fixed by 
transferring the cell suspension into tubes containing 70% 
ethanol on ice. Cells were then centrifuged at 800 × g for 
5 min and the ethanol was thouroughly removed. The cell 
pellet, containing 2.106 cells in 0.5-ml Eppendorf tubes, 
were resuspended in 40 Itl of phosphate-citrate buffer, 
consisting of 192 parts of 0.2 M Na2HPO 4 and 8 parts of 
0.1 M citric acid (pH 7.8), at room temperature, for an 
hour. After centrifugation at 1000 × g for 5 min, the 
supernatant, containing the small DNA fragments, was 
transferred to new tubes and concentrated to a volume of 
25-30 /xl by vacuum in a Hetovac concentrator. 3 /xl 
aliquots of 0.25% Nonidet NP-40 and 10 mg/ml RNAse 
A were then added and the DNA extract was incubated 
overnight at 37°C. 3 /~1 of 1 mg/ml proteinase K was 
added and the extract was incubated further for 2 h. 
Samples were then denatured at 65°C for 5 min and mixed 
with 12 /xl of loading buffer (0.25% bromophenol blue, 
0.25% xylene cyanol FF, 30% glycerol). The entire content 
of the tube was loaded onto 1.2% (w/v) agarose horizon- 
tal slab gels. Electrophoresis was performed in TAE buffer 
(40 mM Tris, 20 mM acetic acid, 1 mM EDTA (pH 8)) for 
18 h at 2 V/cm. DNA was stained with ethidium bromide 
(1 /zg/ml in distilled water) and gels were photographed 
under UV light. A Hin dill digest of A phage DNA was 
used as a standard. 
3. Results 
3.1. Collagen phenotype and Type H transglutaminase 
expression i  chondrocytes at different passages and upon 
retinoic acid treatment 
As main collagen type, differentiated chondrocytes x- 
press type II collagen ([otl(II)] 3) while dedifferentiation 
leads to suppression of type II collagen synthesis and 
initiation of type I ([ al(I)] 2 %(I)), type I trimer ([ O~1(I)]3) 
and type III collagen ([ al(III)] 3) synthesis [28]. 6% SDS- 
PAGE under non-reducing conditions of collagens ex- 
tracted from cell cultures allow separation of type III 
collagen, az(I) chains and ai(I or II) chains [26]. This 
gives useful but incomplete information since ce~ chains 
from type I or II collagens migrate as a single band leading 
to confusion between type II collagen and type I trimer 
collagen synthesis. Therefore, purified collagens were sub- 
jected to cyanogen bromide cleavage since each type of 
collagen chain cleaved by cyanogen bromide leads to a 
specific pattern of peptides on 16% SDS-PAGE (see Fig. 
1). In addition to the examination of the peptides pattern 
obtained, the presence of CB10 (II), CB7(I) and CB 5 + 9 
(III) indicates the synthesis of type II, type I and type III 
collagens respectively. As shown on Fig. 1, chondrocytes 
in primary culture only synthethised type II collagen while 
at passage 2, chondrocytes xpressed a mixture of type I 
and II collagen, showing that these cells were undergoing 
dedifferentiation. At passage 4, chondrocytes expressed 
almost only type I collagen, revealing complete dedifferen- 
tiation. Retinoic acid treatment of cells also caused dedif- 
ferentiation displayed by a down regulation of type II 
collagen synthesis with concomitant switch to collagen I
and III synthesis. 
As shown on Fig. 2, while type II TGase was barely 
detectable in freshly isolated cells from articular cartilage 
and in confluent primary cultures, type II TGase was 
expressed at later passages. Upon retinoic acid treatment of 
cells, type II TGase expression was strongly enhanced 
whatever the passage number. This is consistent with our 
previous results showing approximately a doubling of 
TGase activity in dedifferentiated cells (P2 or P4) upon 
RA treatment [26]. At earlier passages (P0, P1), the in- 
crease of type II TGase upon RA treatment could not be 
anticipated on the basis of activity measurements because 
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DHCB + + + 
S + + + 
RA + + + + + + 
P0 P4 
CB 10 (II) 1> 
4C!1 7 (I) 
CB 11 (II) 1> 41CB 8 (I) 
CB 8 (II) 1> 
CB 9,7 (II) 
CB 12 (II) t> 
t> 
• ,,,CB 5+9 (III) 
4 CB 6 (I) 
4CB 3 (I) 
%CB 4 (III) 
#smal l  CB (Ill) 
Fig. l. 16% SDS-PAGE of CNBr peptides from collagens purified from confluent cultures of chondrocytes in primary culture (P0), passage 2 (P2) and 
passage 4 (P4). As indicated on the figure, confluent cultures were either treated with 3.3 ~M retinoic acid (RA) for 48 h, or with 3 /xM 
dihydrocytochalasin B (DHCB) for 14 days, or 5 nM staurosporin (S) for five days. For each treatment, control cultures were treated similarly with 
medium alone. After DHCB or S treatment, dishes were treated for two days more with either medium containing 3.3/xM RA or with medium alone. Type 
II collagen CNBr peptides (CBn (II)), indicated by open arrowheads, are present in cells expressing a differentiated phenotype. Type I and III collagen 
CNBr peptides (CBn (I) and CBn (III), respectively), indicated by short and long closed arrowheads respectively, are present in cells expressing a 
dedifferentiated phenotype. In addition to the examination of the peptides pattern obtained, CB 10 (11), CB7 (I) and CB 5 + 9(I11) indicates the synthesis of 
type II, type I, and type Ill collagens, respectively. 
I Po P2 P4 
RA + + + 
Fig. 2. Western blot analysis of type II TGase expression in freshly 
isolated chondrocytes (I), chondrocytes in primary culture (Po), passage 2 
(P2) and passage 4 (P4)- Cells were treated or not by 3.3 /xM retinoic acid 
(RA) for 48 h. 30 /xg protein was applied to each lane. Arrow marks the 
position of type II TGase. 
of the presence of the other TGase activity which is 
down-regulated by RA [26]. 
Therefore, type II TGase expression occurred only in 
cells undergoing dedifferentiation a d in dedifferentiated 
cells which could suggest hat the lack of type II TGase 
expression was related to cell differentiation. However, 
type II TGase has also been described to be involved in 
cellular growth, apoptosis or adhesion and complementary 
experiments were performed to address these issues. 
3.2. Type H transglutaminase expression as a function of 
cell growth 
To see whether type II TGase expression was related to 
cell growth, we looked at TGase expression as a function 
of time after seeding in chondrocytes atpassage 2. As can 
be seen on Fig. 3, type II TGase expression was low at day 
one, time necessary for the cells to adhere but not suffi- 
cient for division to start. From day 3 to 5, period of time 
in which cells are in the exponential phase of growth, type 
II TGase expression i creased. After the cells had reached 
confluency, Type II TGase expression progressively de- 
creased. These results suggest hat type II TGase is ex- 
pressed at a higher level when cells are actively dividing 
than when essentially in a non mitotic state. 
A) 
E 1 3 4 5 8 15 25 
~" 200" 
150' 
.~ 100. 
50'  
B) 
0 5 10 15 20  25 
T ime (days) 
Fig. 3. Type II TGase expression as a function of cell growth. A: Western blot analysis of type II TGase expression in chondrocytes at passage 2 as a 
function of days after seeding, as indicated. 30 /a.g protein was applied to each lane. Commercial type II TGase is included as positive control (lane E). B: 
Corresponding growth curve. At the indicated ays, cells were trypsinized and counted. 
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3.3. Collagen phenotype and type H transglutaminase 
expression in DHCB and staurosporin-treated cells 
In order to further analyse whether type II collagen and 
type II TGase expression were related, cells at different 
passages (i.e., at different differentiation states) were 
treated with DHCB or staurosporin for 14 and 5 days, 
respectively after the cells have reached confluency. 
As shown on Fig. 1, DHCB and staurosporin treatment 
of chondrocytes at passage 2 reinduced type II collagen 
synthesis and complete suppression of type I and type III 
collagen synthesis. Moreover, contrary to cells in primary 
culture, RA treatment of these DHCB or staurosporin- 
treated P2 cells was not able to induce overt signs of 
dedifferentiation. At passage 4, DHCB and staurosporin 
were still both able to induce type II collagen synthesis. 
However, unlike DHCB, staurosporin was not able any 
more to totally suppress type I collagen synthesis. 
As shown on Fig. 4, confluency for 14 days induced a 
decrease of type II TGase expression compared to newly 
confluent cells, in particular from P0 to P2. This confirms 
results presented on Fig. 3 for P2 cells. However, at P3 
and P4, the decrease of type II TGase expression was not 
noticeable. Moreover, while retinoic acid increased type II 
TGase expression in post confluent P0 to P2 cells, as it 
does in newly confluent cells, it was almost ineffective on 
post confluent P3 and P4 cells. 
E 
. . + + DHCB 
+ + . + RA 
P0 
Pl 
P2 
P3  
. . . . . . .  ~ ' P4  
Fig. 4. Western blot analysis of type II TGase expression i  chondrocytes 
at different passages (Po to P4). As indicated, confluent cultures were 
either treated with 3.3 /xM retinoic acid (RA) for 48 h, or with 3 /~M 
dihydrocytochalasin B (DHCB). For each treatment, control cultures were 
treated similarly with medium alone. After DHCB treatment, dishes were 
treated for two days more with either medium containing 3.3 /zM RA or 
with medium alone. 60 p~g protein was applied to each lane. Commercial 
type 11 TGase is included as positive control (lane E). 
Po P2 
S - + - + 
Fig. 5. Western blot analysis of type II TGase expression i  chondrocytes 
in primary culture (P0) and passage 2 (P2). Confluent dishes were treated 
or not with 5nM staurosporin (S) for 5 days, as indicated. 60/zg protein 
was applied to each lane. Arrow marks the posistion of type 1I TGase. 
In primary cultures, which display a differentiated phe- 
notype, DHCB did not modify TGase expression compared 
to control cells kept post confluent for 14 days while at 
passage 1and 2, where chondrocytes undergo dedifferenti- 
ation, DHCB treatment of cells depressed type II TGase 
expression compared to control (Fig. 4). Further treatment 
with RA induced a slight increase of type II TGase expres- 
sion. Based on these results, the hypothesis of an inverse 
relationship between type II collagen synthesis and type II 
TGase expression would tend to be strengthened. How- 
ever, at passage 3 and 4, although DHCB was still able to 
induce type II collagen reexpression, type II TGase expres- 
sion was not modified whether the cells were treated or not 
by DHCB and RA. Moreover, as shown on Fig. 5, stau- 
rosporin treatment induced an increase of type II TGase 
expression whatever the passage number, i.e. the differen- 
tiation state of the cells. 
Therefore, although results from the first section sug- 
gested that there could be an inverse relationship between 
type II collagen synthesis and type II TGase expression, 
these results clearly indicate that type II collagen expres- 
sion is not incompatible with type II TGase expression 
since DHCB-treated cells at passage 3 and 4 as well as 
staurosporin-treated c lls do express both type II TGase 
and type II collagen. 
3.4. Cell morphology and adhesion of RA, DHCB and 
staurosporin-treated cells 
When freshly isolated from cartilage, chondrocytes x- 
hibit a low capacity to adhere to plastic dishes since they 
need 48 h to adhere. At this stage, they exhibit a round 
morphology (Fig. 6A). When primary cultures are conflu- 
ent, they display a polygonal morphology (Fig. 6B). As the 
passage number increases, subcultured cells show a more 
and more extended, flattened morphology that reflects 
increased adhesion of the cells to the substratum (Fig. 
6C)[29], RA and staurosporin treatment increased cell 
spreading (Fig. 6D and F respectively) whereas DHCB 
induced cell rounding and cell release from the substratum, 
these cells being alive (Fig. 6E). The proportion of 
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DHCB-treated cells detaching from the Petri dish was 
greater when the passage number was low (not shown). 
There is therefore a positive correlation between type II 
TGase expression and cell adhesion. 
3.5. Detection o f  apoptosis in retinoic acid, dihydrocy- 
tochalasin B and staurosporin-treated cells 
Type II TGase has been shown to be induced upon 
apoptosis, participating to the formation of apoptotic bod- 
ies [4,12,13], and agents used in these studies have been 
described to induce apoptosis in other cellular models 
([33,34] for RA and staurosporin, respectively). It was 
therefore of interest to study whether these compounds 
were able to induce apoptosis in our cell culture condi- 
tions, in particular when an increase of type II TGase was 
observed. DHCB and staurosporin modify the cytoskeleton 
architecture [41,42], preventing apoptotic bodies formation 
although nucleosomal fragmentation occurs [43]. Apopto- 
sis detection by morphologic observation of such treated 
cells was therefore not suitable. Thus, agarose gel elec- 
trophoresis of DNA, the other standard method for apopto- 
sis detection, was performed. However, whether apoptosis, 
and whether nucleosomal fragmentation could occur in 
chondrocytes had never been shown. Preliminary experi- 
ments indicated that chondrocytes treated for 24 h with 
DHCB or staurosporin at a concentration 20 times higher 
than routinely used for redifferentiation both lead to nucle- 
Fig. 6. Cell morphology. Phase micrographs of freshly isolated cells three days after seeding (A), confluent primary cultures (B). confluent cells at passage 
2 (C), confluent cells at passage 2 treated with 3.3 p.M retinoic acid for 48 h (D), confluent cells at passage 2 treated with 3/xM dihydrocytochalasin B for 
14 days (E) and confluent cells at passage 2 treated with 5 nM staurosporin for 5 days (F). 200 X magnification. 
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Fig. 7. Agarose gel electrophoresis DNA extracted from chondrocytes at
passage 2 treated with 3.3/zM retinoic acid (RA) for 48 h, or with 3 p,M 
dihydrocytochalasin B (DHCB) for 14 days, or 5 nM staurosporin (S) for 
five days. For each treatment, control cultures were treated similarly with 
medium alone. Cells treated with 60 /zM DHCB or 100 nM S for 24 h 
are also included as positive control of nucleosomal fragmentation i
chondrocytes (lanes 2 and 9, respectively). The migration of hHindlII 
mol. wt. markers are shown for comparison (lanes 1 and 10). Each lane 
corresponds to the small DNA fragments extracted from 2.106 cells. 
osomal fragmentation (Fig. 7, lane 2 and 9). Apoptosis 
could therefore occur in chondrocytes and the method 
chosen for apoptosis detection was appropriate. As seen on 
Fig. 7, in our cell culture conditions, staurosporin was able 
to induce nucleosomal fragmentation at a low level whereas 
DHCB and RA were ineffective. The increase of type II 
TGase expression upon RA treatment is therefore not due 
to cell apoptosis while it may be upon staurosporin treat- 
ment. 
4. Discussion 
Depending on the cell type studied, type II TGase has 
been implicated in many events of the cell life such as 
differentiation [9-11], growth [7,8], cell adhesion [17,18], 
cell matrix stabilisation [6,20-22] or apoptosis [12-14] 
and the purpose of this paper was to point out the field(s) 
where type II TGase may take an active part in chondro- 
cytes. 
Type II TGase was barely detectable in freshly isolated 
articular chondrocytes and weakly expressed in confluent 
primary cultures. This is consistent with the observations 
of Aeschlimann and Paulsson [44] who did not detect any 
type II TGase by immunostaining of articular cartilage 
slices. Upon subculture, which leads to chondrocyte dedif- 
ferentiation, type II TGase expression increased up to 
passage 3 then routinely decreased at P4 (Fig. 4). Type II 
TGase expression as a function of passage number there- 
fore appears as a bell-shaped curve. Interestingly, from 
passage 4, we previously showed that chondrocytes display 
a senescent phenotype, characterized in particular by a 
decrease of the proliferative capacity [27]. Moreover, as 
shown on Fig. 3, type II TGase expression was high when 
cells were in the exponential phase of growth while it was 
low one day after cell seeding (when cells have not started 
yet to divide) and when cells were kept post-confluent. As
previously shown [[45] and unpublished ata], most of the 
chondrocytes are in the G0-G1 phases of the cell cycle 
when confluent or when plated the day before while an 
important percentage of the cells are in the S and/or 
G2 + M phases of the cell cycle during the exponential 
phase of growth. These results suggest hat type II TGase 
expression is increased uring the S and/or G2 + M phases 
of the cell cycle compared to the G0-G1 phases. Our 
results are in agreement with those of Aeschlimann and 
Paulsson who found that resting cartilage cells from the 
growth plate were devoid of type II TGase which only 
appeared in the proliferation/maturation z e [44]. How- 
ever, it has usually been shown that TGase activity and 
mRNA levels are highest when cells are in a non-mitotic 
state but the cells studied were either of tumor origin [7], 
and tumor cells do not behave similarly to normal cells as 
far as cell growth regulation is concerned, or were normal 
cells chemically blocked in a certain phase of the cell 
cycle [8]. 
Upon retinoic acid treatment, ype II TGase expression 
was greatly enhanced and parallelled the TGase activity 
data [26]. Whereas retinoic acid promotes differentiation f
monocytes or HL60 cells into macrophages [10,11] but 
induces dedifferentiation f chondrocytes [30] and kera- 
tinocytes [9], it always induced an increase of type II 
TGase expression in the cells of different embryologic 
origins tested [4], including chondrocytes a shown in this 
paper. Since type II TGase was expressed in subculture 
and upon retinoic acid treatment, which both induce cell 
dedifferentiation, we theorized that the lack of type II 
TGase expression was associated with the differentiated 
phenotype of the chondrocyte, assessed by type II collagen 
synthesis. However, although DHCB treatment of cells at 
passage 2 reinduced type II collagen synthesis and an 
arrest of type II TGase expression, which tended to con- 
firm our hypothesis, DHCB treated cells at P4 or stau- 
rosporin-treated cells both expressed type II TGase and 
type II collagen. Although the increase of type II TGase 
expression upon staurosporin treatment may also be due to 
cell apoptosis, the results obtained with the DHCB-treated 
cells clearly show that type II TGase expression is not 
incompatible with type II collagen expression. 
While DHCB and staurosporin both reinduce type II 
collagen synthesis, they have opposite ffects on cell adhe- 
sion. Results showed that freshly isolated cells as well as 
DHCB-treated cells had a round morphology, were weakly 
adherent and expressed a low amount of type II TGase 
124 L. Borge et aL / Biochimica et Biophysica Acta 1312 (1996) 117-124 
while subcultured, retinoic acid- and staurosporin-treated 
cells were spread, adherent and expressed a high amount 
of type II TGase (Fig. 6). This strong positive correlation 
between type II TGase expression and cell adhesion in 
these cell culture systems suggests that the physiological 
lack of TGase expression in freshly isolated articular chon- 
drocytes is to be related to their incapabil ity to adhere to a 
plastic dish. A parallel between cell adhesion and type II 
TGase expression has already been described in other cell 
systems. For example, the differentiation of blood mono- 
cytes (non adherent cells) into macrophages (adherent 
cells) parallels type II TGase expression [11]. Also, Genti le 
et al. [l 8] showed an increased cell adhesion upon transfec- 
tion of 3T3 fibroblasts with a TGase expression plasmid. 
In conclusion, we suggest hat type II TGase is involved 
in the process of chondrocyte adhesion. Of course, the role 
played by type II TGase depends on its enzymatic activity 
on specific substrates. Many proteins have been shown to 
be substrates of type II TGase, in particular proteins of the 
extracellular matrix such as fibronectin, collagens [4,20-  
22] and more recently osteonectin [6], for example. Since 
the expression of many of these proteins can be easily 
modulated in chondrocytes when cultured in various condi- 
tions, chondrocytes may constitute a suitable model for 
these studies. 
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